Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04233814
Recruitment Status : Recruiting
First Posted : January 18, 2020
Last Update Posted : September 9, 2021
Sponsor:
Information provided by (Responsible Party):
Lung Therapeutics, Inc

Brief Summary:

The current study will investigate the initial safety, tolerability, and PK profile of inhaled LTI-03 in healthy volunteers. In order to minimize exposure, the study will first test single ascending doses (SAD) of LTI-03 followed by multiple ascending dose (MAD) cohorts.

Findings from this study will direct the clinical development of LTI-03 for the treatment of IPF

The study subject population will include normal healthy male and female volunteers between 18 and 55 years of age (inclusive).

Consistent with other trials involving inhaled medication, subjects must have normal pulmonary function at Screening and will be excluded if they have a history of active or recurring allergies, asthma, chronic obstructive pulmonary disease (COPD), chronic sinus drainage, chronic or acute cough or other respiratory condition deemed exclusionary by the Investigator. History of liver dysfunction or elevated bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values at Screening will also be grounds for exclusion.


Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The first part of the study will follow a Single Ascending Dose design. Subjects receive a single dose of double-blind study medication (investigational medicinal product LTI-03 or placebo) on Day 1.

For each dose level cohort, two eligible sentinel subjects will be randomized in a 1:1 ratio to receive active:placebo study medication.

If no tolerability issues are observed by the Investigator within 48 hours post-dose, dosing will commence for the remaining six subjects in the cohort, who will be randomized in a 5:1 ratio to receive active:placebo study medication.

The second part of the study will follow a Multiple Ascending Dose design. Subjects receive double-blind study medication (LTI-03 or placebo) once-daily from Day 1 to Day 14.

For each dose level cohort, eight eligible subjects will be randomized in a 6:2 ratio to receive active:placebo study medication.

Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:

The Sponsor, Investigator, and study personnel working on behalf of the Investigator and Sponsor will remain blinded.

Study medication will be dispensed by unblinded pharmacy staff to study staff in a blinded manner. Other than the pharmacist(s), all study staff will remain blinded to study medication assignment.

Primary Purpose: Other
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects
Actual Study Start Date : January 20, 2020
Estimated Primary Completion Date : December 22, 2021
Estimated Study Completion Date : December 22, 2021


Arm Intervention/treatment
Sham Comparator: Placebo
Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
Drug: Placebo
Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.

Experimental: SAD Cohort 1
LTI-03 20 mg delivered qd x 1 day via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: SAD Cohort 2
LTI-03 40 mg delivered qd x 1 day via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: SAD Cohort 3
LTI-03 80 mg delivered qd x 1 day via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: MAD Cohort 1
LTI-03 dose at 20mg once daily x 14 days via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: MAD Cohort 2
LTI-03 dose at 40mg once daily x 14 days via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: MAD Cohort 3
LTI-03 dose at 2.5 mg once daily x 14 days via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: MAD Cohort 4
LTI-03 dose at 5 mg once daily x 14 days via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

Experimental: MAD Cohort 5
LTI-03 dose at 5 mg twice daily x 14 days via DPI
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events (TEAE) [ Time Frame: up to 49 days ]
    Incidence of TEAE by system-organ class and dose group as assessed by the Toxicity Grading Scale for Healthy Adult Volunteers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Non-smoker (no use of tobacco products within 6 months prior to dosing) with a negative urine cotinine test at Screening or Day -1
  2. Age of 18-55 years (inclusive)
  3. Body mass index (BMI) of 18 - 30.5 kg/m2 (inclusive)
  4. Body weight > 50 kg
  5. Willing and able to provide written informed consent

Exclusion Criteria:

  1. History of asthma
  2. Presence of active or recurring allergies, asthma, chronic obstructive pulmonary disease (COPD), chronic sinus drainage, chronic or acute cough or other respiratory condition deemed exclusionary by the Investigator or designee
  3. Pulmonary infiltrate or pneumonia within 6 months prior to dosing or acute infection within 14 days prior to dosing
  4. History of significant allergy or anaphylaxis
  5. Any clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease (excluding hay fever), as determined by the Investigator or designee
  6. Any current clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and heart rate measurement, and clinical laboratory tests (hematology, coagulation, urinalysis, clinical chemistries) at Screening or Day -1, as determined by the Investigator or designee
  7. Any clinically significant illness and/or surgery within 28 days prior to dosing
  8. Febrile illness within 7 days prior to dosing
  9. Weight loss > 5 kg within 28 days prior to dosing
  10. Clinically significant 12-lead electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure < 90 mmHg or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 90 mmHg, or heart rate < 45 beats per minute [bpm] or > 100 bpm) at Screening or Day -1, as determined by the Investigator or designee
  11. History of, or existing severe, acute, chronic, and/or psychiatric medical condition(s), laboratory abnormality, or other medical concerns that may increase the risk associated with study participation or IMP administration which, in the judgment of the Investigator, would make the subject inappropriate for entry into the study
  12. History of cancer with the exception of adequately treated basal cell or squamous cell carcinoma of the skin
  13. Hemoglobin < lower limit of normal (LLN)
  14. Abnormal liver function- alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of the normal range (ULN)

    - total bilirubin > 1.5 times ULN

  15. Abnormal renal function: estimated glomerular filtration rate (eGFR) (modification of diet and renal disease [MDRD]) < 55 mL/min/1.73 m2
  16. Pulmonary function outside the normal range, including forced expiratory volume 1 (FEV1), forced vital capacity (FVC) each < 80% of predicted or FEV1/FVC ratio of ≤ 0.7 at Screening
  17. Inability to use study inhaler device appropriately.
  18. Positive test results for human immunodeficiency virus (HIV) HIV-1/HIV-2 antibodies, hepatitis B surface antigen (HBsAG) or hepatitis C virus antibody (HCV-AB) Concurrent Intake of Other Substances
  19. History of alcohol abuse within one year prior to Screening or regular use of alcohol of ≥ 14 units of alcohol per week for females and ≥ 21 units of alcohol for males (1 unit = 150 mL wine, 360 mL beer or 45 mL of 40% alcohol) within 6 months prior to dosing or a positive urine alcohol test at Screening or Day -1
  20. History of drug abuse or misuse within 5 years prior to dosing or a positive urine drug test at Screening or Day -1
  21. Inability or unwillingness to abstain from alcohol or any drug of abuse for 48 hours prior to the first dose until completion of the Day 8 visit for the SAD and Day 21 visit for the MAD
  22. Exposure to any live vaccines within 28 days prior to dosing
  23. Treatment with an investigational product within 30 days or 5 half-lives (whichever is longer) prior to dosing
  24. Use of prescription or non-prescription medications and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to dosing. Approved medications taken for contraception are permitted.
  25. Positive serum pregnancy test in female subjects
  26. Female subjects who are lactating
  27. Female subjects of childbearing potential (FOCBP) and men with partners of childbearing potential who do not agree to use an acceptable form of contraception for the duration of study treatment and for at least 90 days after the last dose of study medication. Male subjects who do not agree to refrain from donating sperm during this same period.
  28. Not eligible to receive study medication within 2 weeks of receiving a COVID-19 vaccination, including an initial, second, or booster injection.

NOTE: Female who is surgically sterile or post-menopausal for at least 12 months with follicle stimulating hormone (FSH) > 30 mIU/ml, are not considered to be of childbearing potential.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04233814


Contacts
Layout table for location contacts
Contact: Laura Emery, MSPH 3039026306 lemery@lungtx.com
Contact: Anne Kinney, MSPH 7204704743 akinney@lungtx.com

Locations
Layout table for location information
United Kingdom
Celerion Recruiting
Belfast, United Kingdom, BT9 6AD
Contact: Grace Taylor-Holmes       grace.taylor-holmes@celerion.com   
Contact: Jemma Morrison    +44 0 28 90 554067    jemma.morrison@celerion.com   
Sponsors and Collaborators
Lung Therapeutics, Inc
Investigators
Layout table for investigator information
Principal Investigator: Devinda Weeraratne, MD Celerion
Layout table for additonal information
Responsible Party: Lung Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT04233814    
Other Study ID Numbers: LTI-03-1001
First Posted: January 18, 2020    Key Record Dates
Last Update Posted: September 9, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases
Respiratory Tract Diseases